0000950170-24-073851.txt : 20240614 0000950170-24-073851.hdr.sgml : 20240614 20240614180251 ACCESSION NUMBER: 0000950170-24-073851 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240614 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CHESS ROBERT CENTRAL INDEX KEY: 0001227886 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 241046305 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 ownership.xml 4 X0508 4 2024-06-14 0000906709 NEKTAR THERAPEUTICS NKTR 0001227886 CHESS ROBERT C/O NEKTAR THERAPEUTICS 455 MISSION BAY BLVD SOUTH SAN FRANCISCO CA 94158 true false false false true Common Stock 2024-06-14 4 S false 19500 1.20 D 255273 D Common Stock 2100 I by daughter Common Stock 2100 I by son Common Stock 2100 I by daughter This transaction was made pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $1.19 to $1.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose. Mark A. Wilson, Attorney-in-Fact 2024-06-14